Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.
Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.
复制标题
DOI：
10.1016/j.addr.2012.09.041
复制
发表时间：
2013-01
影响因子：
16.1
通讯作者：
Hamm-Alvarez, Sarah F.
中科院分区：
文献类型：
--
作者：
Xu, Shi;Olenyuk, Bogdan Z.;Okamoto, Curtis T.;Hamm-Alvarez, Sarah F.
利用受体介导的内吞途径靶向药物及其载体系统在25年前还处于初级阶段。在这中间的几年里，对纳米颗粒递送系统的设计和合成以及对先前被称为受体介导的内吞作用的细胞复杂性的阐明的知识的爆炸，现在创造了一种情况，当设计和测试将高度特异性的纳米颗粒药物载体递送到特定细胞和组织的可行性成为可能。这篇综述概述了药物递送中受体介导的内吞作用的主要模式的机制，并强调了最近使用这些作为纳米颗粒体内药物递送靶点的方法。本文还讨论了从配体-药物偶联物到配体-纳米颗粒偶联物的简单转变所带来的一些内在复杂性，包括配体价及其与受体介导的内化模式的关系。
Targeting of drugs and their carrier systems by using receptor-mediated endocytotic pathways was in its nascent stages 25 years ago. In the intervening years, an explosion of knowledge focused on design and synthesis of nanoparticulate delivery systems as well as elucidation of the cellular complexity of what was previously-termed receptor-mediated endocytosis has now created a situation when it has become possible to design and test the feasibility of delivery of highly specific nanoparticle drug carriers to specific cells and tissue. This review outlines the mechanisms governing the major modes of receptor-mediated endocytosis used in drug delivery and highlights recent approaches using these as targets for in vivo drug delivery of nanoparticles. The review also discusses some of the inherent complexity associated with the simple shift from a ligand-drug conjugate versus a ligand-nanoparticle conjugate, in terms of ligand valency and its relationship to the mode of receptor-mediated internalization.
登录
查看更多内容
影响因子：
8
作者：
通讯作者：
--
影响因子：
15
作者：
Boger, DL;Goldberg, J;Cheresh, DA
通讯作者：
Cheresh, DA
DOI：
10.2217/17435889.2.3.375
发表时间：
2007-06-01
期刊：
Nanomedicine (London, England)
影响因子：
--
作者：
Corbin, Ian R;Zheng, Gang
通讯作者：
Zheng, Gang
影响因子：
64.5
作者：
Brooks, PC;Stromblad, S;Cheresh, DA
通讯作者：
Cheresh, DA
影响因子：
5.7
作者：
Chen H;Ahn R;Van den Bossche J;Thompson DH;O'Halloran TV
通讯作者：
O'Halloran TV